

DAFTAR PUSTAKA

- Achmad, A.F., Raharjani, Y.I., Setyaningrum, Z., Pramono, B.A., dan Selviana, D.R., 2022. Anticoagulant Therapy in Moderate to Severe COVID-19 Patients | Achmad | Mutiara Medika: Jurnal Kedokteran dan Kesehatan. *Mutiara Medika : Jurnal Kedokteran dan Kesehatan*, Volume 22: 69–74.
- Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., dkk., 2020. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. *EClinicalMedicine*, 27: 100562.
- American Pharmacists Association, 2021. *Adult Drug Information Handbook*, 30th edition. ed. Lexi- Comp, Inc.
- Araf, Y., Akter, F., Tang, Y., Fatemi, R., Parvez, Md.S.A., Zheng, C., dkk., 2022. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. *Journal of Medical Virology*, 94: 1825–1832.
- Azer, S.A., 2020. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. *New Microbes and New Infections*, 37: 100738.
- Azizah, N.F., Faizah, R.N., Primasanti, D., Prihantini, I.K., dan Romadhian, I.G., 2022. Efektifitas Penggunaan Enoxaparin dan Fondaparinux Sebagai Antikoagulan Pada Pasien Covid-19 di RSUD Sidoarjo. *Majalah Farmaseutik*, 18: 57–64.
- Barbar, S., Noventa, F., Rossetto, V., Ferrari, A., Brandolin, B., Perlati, M., dkk., 2010. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *Journal of Thrombosis and Haemostasis*, 8: 2450–2457.
- Bick, R.L., Frenkel, E.P., Walenga, J., Fareed, J., dan Hoppensteadt, D.A., 2005. Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use. *Hematology/Oncology Clinics of North America*, 19: 1–51.
- Biswas, M., Rahaman, S., Biswas, T.K., Haque, Z., dan Ibrahim, B., 2021. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology*, 64: 36–47.

- Bliek-Bueno, K., Mucherino, S., Poblador-Plou, B., González-Rubio, F., Aza-Pascual-Salcedo, M., Orlando, V., dkk., 2021. Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy. *International Journal of Environmental Research and Public Health*, **18**: 11786.
- Campbell, C.M. dan Kahwash, R., 2020. Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? *Circulation*, **141**: 1739–1741.
- Center for Disease Control and Prevention, 2023. 'Risk for COVID-19 Infection, Hospitalization, and Death By Age Group', *Centers for Disease Control and Prevention*. URL: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html> (diakses tanggal 31/5/2023).
- COVIDSurg, C. dan GlobarSurg, C., 2022. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. *Anaesthesia*, **77**: 28–39.
- Dahlan, S., 2019. *Analisis Multivariat Regresi Logistik*, Edisi 2. PT Epidemiologi Indonesia, Jakarta.
- de Wit, E., van Doremalen, N., Falzarano, D., dan Munster, V.J., 2016. SARS and MERS: recent insights into emerging coronaviruses. *Nature Reviews Microbiology*, **14**: 523–534.
- Decousus, H., Tapson, V.F., Bergmann, J.-F., Chong, B.H., Froehlich, J.B., Kakkar, A.K., dkk., 2011. Factors at Admission Associated With Bleeding Risk in Medical Patients: Findings From the IMPROVE Investigators. *CHEST*, **139**: 69–79.
- Demelo-Rodriguez, P., Farfán-Sedano, A.I., Pedrajas, J.M., Llamas, P., Sigüenza, P., Jaras, M.J., dkk., 2021. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. *Journal of Thrombosis and Haemostasis*, **19**: 1981–1989.
- Dessie, Z.G. dan Zewotir, T., 2021. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. *BMC Infectious Diseases*, **21**: 855.
- Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeli, S.-M., dan Bahreini, E., 2020. A comprehensive review of COVID-19 characteristics. *Biological Procedures Online*, **22**: 19.

European Society of Cardiology, 2020. 'Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers', . URL: [https://www.escardio.org/Councils/Council-on-Hypertension-\(CHT\)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang), [https://www.escardio.org/Councils/Council-on-Hypertension-\(CHT\)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang) (diakses tanggal 19/8/2022).

Fan, B.E., Chong, V.C.L., Chan, S.S.W., Lim, G.H., Lim, K.G.E., Tan, G.B., dkk., 2020. Hematologic parameters in patients with COVID-19 infection. *American Journal of Hematology*, **95**: E131–E134.

Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W., dkk., 2003. Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin. *Clinical Pharmacokinetics*, **42**: 1043–1057.

Flumignan, R.L., Civile, V.T., Tinôco, J.D. de S., Pascoal, P.I., Areias, L.L., Matar, C.F., dkk., 2022. Anticoagulants for people hospitalised with COVID-19. *Cochrane Database of Systematic Reviews*, .

Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Brown, J.Q., dan Heide, R.S.V., 2020. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *The Lancet Respiratory Medicine*, **8**: 681–686.

Fu, Z., Huang, Z., Huang, W., dan Huang, K., 2020. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. *The American Journal of Emergency Medicine*, **38**: 641–647.

Garcia, D.A., Baglin, T.P., Weitz, J.I., dan Samama, M.M., 2012. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **141**: e24S-e43S.

Gold, M.S., Sehayek, D., Gabrielli, S., Zhang, X., McCusker, C., dan Ben-Shoshan, M., 2020. COVID-19 and comorbidities: a systematic review and meta-analysis. *Postgraduate Medicine*, **132**: 749–755.

Gomez, J.M.D., Du-Fay-de-Lavallaz, J.M., Fugar, S., Sarau, A., Simmons, J.A., Clark, B., dkk., 2021. Sex Differences in COVID-19 Hospitalization and Mortality. *Journal of Women's Health*, **30**: 646–653.

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., dkk., 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*, **382**: 1708–1720.

He, X., Yao, F., Chen, J., Wang, Y., Fang, X., Lin, X., dkk., 2021. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Scientific Reports*, **11**: 1830.

Hidayati, S.N., 2022. 'Perbandingan Efektivitas dan Keamanan Penggunaan Antikoagulan Profilaksis Unfractionated Heparin dan Enoxaparin pada Pasien COVID-19', . Universitas Gadjah Mada, Yogyakarta.

Hirsh, J., Anand, S.S., Halperin, J.L., dan Fuster, V., 2001. Mechanism of Action and Pharmacology of Unfractionated Heparin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **21**: 1094–1096.

Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., Kovacs, M.J., dkk., 2012. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **141**: e152S-e184S.

Hu, D., Lou, X., Meng, N., Li, Z., Teng, Y., Zou, Y., dkk., 2021. Influence of age and gender on the epidemic of COVID-19. *Wiener klinische Wochenschrift*, **133**: 321–330.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., dkk., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, **395**: 497–506.

Hull, R., Garcia, D.A., dan Burnett, A., 2022. 'Heparin and LMW heparin: Dosing and adverse effects', . URL: <https://www.uptodate.com/contents/heparin-and-lmw-heparin-dosing-and-adverse-effects> (diakses tanggal 29/10/2022).

Iba, T., Levy, J.H., Levi, M., dan Thachil, J., 2020. Coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*, **18**: 2103–2109.

INSPIRATION Investigators, 2021. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. *JAMA*, **325**: 1620–1630.

Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., dkk., 2020. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health*, **8**: 152.

Kaatz, S., Ahmad, D., Spyropoulos, A.C., dan Schulman, S., 2015. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients:

communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **13**: 2119–2126.

Kan, C., Zhang, Y., Han, F., Xu, Q., Ye, T., Hou, N., dkk., 2021. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. *Frontiers in Endocrinology*, **12**: .

Khajuria, A., Bobdey, S., Kumar, S., Sahu, R., Vashisht, R., Bhaskar, V., dkk., 2021. An Analysis of Length of Hospital Stay of COVID-19 Patients Admitted in a Dedicated COVID-19 Hospital. *Journal of Marine Medical Society*, **23**: 145.

Khan, A., Althunayyan, S., Alsofayan, Y., Alotaibi, R., Mubarak, A., Arafat, M., dkk., 2020. Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia. *Eastern Mediterranean Health Journal*, **26**: 1371–1380.

Klok, F.A., Kruip, M.J.H.A., Meer, N.J.M. van der, Arbous, M.S., Gommers, D. a. M.P.J., Kant, K.M., dkk., 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*, **191**: 145–147.

Kollias, A., Kyriakoulis, K.G., Dimakakos, E., Poulakou, G., Stergiou, G.S., dan Syrigos, K., 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. *British Journal of Haematology*, **189**: 846–847.

Lagunas-Rangel, F.A., 2020. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *Journal of Medical Virology*, **92**: 1733–1734.

Lai, C.-C., Wang, C.-Y., Wang, Y.-H., Hsueh, S.-C., Ko, W.-C., dan Hsueh, P.-R., 2020. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. *International Journal of Antimicrobial Agents*, **55**: 105946.

Lemeshow, S., Hosmer, D.W., Klar, J., Lwanga, S.K., dan World Health Organization, 1990. *Adequacy of Sample Size in Health Studies*. Wiley, Chichester.

Levi, M., Eerenberg, E., dan Kamphuisen, P.W., 2011. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. *Journal of thrombosis and haemostasis: JTH*, **9**: 1705–1712.

- Levi, M., Toh, C.H., Thachil, J., dan Watson, H.G., 2009. Guidelines for the diagnosis and management of disseminated intravascular coagulation. *British Journal of Haematology*, **145**: 24–33.
- Lexicomp, 2022a. *Fondaparinux : Drug Information*. Wolter Kluwer Health, Inc. Riverwoods.
- Lexicomp, 2022b. *Heparin : Drug Information*. Wolter Kluwer Health, Inc. Riverwoods.
- Lexicomp, 2022c. *Enoxaparin : Drug Information*. Wolter Kluwer Health, Inc. Riverwoods.
- Li, X., Geng, M., Peng, Y., Meng, L., dan Lu, S., 2020. Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis*, **10**: 102–108.
- Linkins, L.-A., Dans, A.L., Moores, L.K., Bona, R., Davidson, B.L., Schulman, S., dkk., 2012. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *CHEST*, **141**: e495S-e530S.
- Liu, Yuwei, Du, X., Chen, J., Jin, Y., Peng, L., Wang, H.H.X., dkk., 2020. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *The Journal of Infection*, **81**: e6–e12.
- Liu, Ying, Gayle, A.A., Wilder-Smith, A., dan Rocklöv, J., 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *Journal of Travel Medicine*, **27**: taaa021.
- Liu, Z., Ji, S., Sheng, J., dan Wang, F., 2014. Pharmacological effects and clinical applications of ultra low molecular weight heparins. *Drug Discoveries & Therapeutics*, **8**: 1–10.
- Long, B., Brady, W.J., Koyfman, A., dan Gottlieb, M., 2020. Cardiovascular complications in COVID-19. *The American Journal of Emergency Medicine*, **38**: 1504–1507.
- Lopes, R.D., Silva, P.G.M. de B. e, Furtado, R.H.M., Macedo, A.V.S., Bronhara, B., Damiani, L.P., dkk., 2021. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *The Lancet*, **397**: 2253–2263.
- Mai, F., Pinto, R.D., dan Ferri, C., 2020. COVID-19 and cardiovascular diseases. *Journal of Cardiology*, **76**: 453–458.

- Mauro, A., De Grazia, F., Lenti, M.V., Penagini, R., Frego, R., Ardizzone, S., dkk., 2021. Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. *Clinics and Research in Hepatology and Gastroenterology*, **45**: 101521.
- McGonagle, D., Sharif, K., O'Regan, A., dan Bridgewood, C., 2020. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmunity Reviews*, **19**: 102537.
- Medscape, 2023. 'Drug Interactions Checker - Medscape Drug Reference Database'. URL: <https://reference.medscape.com/drug-interactionchecker> (diakses tanggal 26/6/2023).
- Nakamura, J., Tsujino, I., Yachi, S., Takeyama, M., Nishimoto, Y., Konno, S., dkk., 2022. Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. *Thrombosis Journal*, **20**: 53.
- Nguyen, A., Dasgupta, A., dan Wahed, A., 2016. Chapter 1 - Coagulation-Based Tests and Their Interpretation, dalam: Nguyen, A., Dasgupta, A., dan Wahed, A. (Editor), *Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients*. Elsevier, hal. 1–16.
- Niazta, N.A., Karimullah, M.D.H., Putra, W.S., Nisa', N.K., Nuraini, P.E., dan Prasetya, S.U., 2021. D-dimer Levels as Novel Biomarker Predictor for All-cause Inhospital Mortality Risk in COVID-19 Patients. *Heart Science Journal*, **2**: 14–19.
- Nutescu, E., Burnett, A., Fanikos, J., Spinler, S., dan Wittkowsky, A., 2016. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **41**: 15–31.
- Olczak-Pruc, M., Swieczkowski, D., Ladny, J.R., Pruc, M., Juarez-Vela, R., Rafique, Z., dkk., 2022. Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. *Nutrients*, **14**: 4217.
- Oudkerk, M., Büller, H.R., Kuijpers, D., van Es, N., Oudkerk, S.F., McLoud, T., dkk., 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. *Radiology*, **297**: E216–E222.
- Patanavanich, R. dan Glantz, S.A., 2020. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. *Nicotine & Tobacco Research*, **22**: 1653–1656.

- Patel, C., Parmar, K., Patel, D., Patel, S., Sheth, D., dan Beladiya, J.V., 2022. Effect of corticosteroid therapy on mortality in COVID-19 patients—A systematic review and meta-analysis. *Reviews in Medical Virology*, **32**: e2386.
- Patel, S.K., Velkoska, E., dan Burrell, L.M., 2013. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? *Clinical and Experimental Pharmacology and Physiology*, **40**: 551–559.
- Pawlowski, C., Venkatakrishnan, A.J., Kirkup, C., Berner, G., Puranik, A., O'Horo, J.C., dkk., 2021. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. *eClinicalMedicine*, **33**: .
- Penninger, J.M., Zhang, H., Li, Y., Zhong, N., dan Slutsky, A.S., 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Medicine*, **46**: 586–590.
- Perepu, U.S., Chambers, I., Wahab, A., Ten Eyck, P., Wu, C., Dayal, S., dkk., 2021. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. *Journal of Thrombosis and Haemostasis*, **19**: 2225–2234.
- Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, dan Ikatan Dokter Anak Indonesia, 2020. *Buku Pedoman Tatalaksana COVID-19 Edisi 3 (Desember 2020)*, 3rd ed. Jakarta.
- Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, dan Ikatan Dokter Anak Indonesia, 2022. *Buku Pedoman Tatalaksana COVID-19 Edisi 4 (Januari 2022)*, 4th ed. Jakarta.
- Perlman, S. dan Netland, J., 2009. Coronaviruses post-SARS: update on replication and pathogenesis. *Nature Reviews. Microbiology*, **7**: 439–450.
- Poudel, R., Daniels, L.B., DeFilippis, A.P., Hamburg, N.M., Khan, Y., Keith, R.J., dkk., 2022. Smoking is associated with increased risk of cardiovascular events, disease severity, and mortality among patients hospitalized for SARS-CoV-2 infections. *PLOS ONE*, **17**: e0270763.
- Priya, S., Selva Meena, M., Sangumani, J., Rathinam, P., Brinda Priyadharshini, C., dan Vijay Anand, V., 2021. “Factors influencing the outcome of COVID-19 patients admitted in a tertiary care hospital, Madurai.- a cross-sectional study.” *Clinical Epidemiology and Global Health*, **10**: 100705.

- Russo, V., Cardillo, G., Viggiano, G.V., Mangiacapra, S., Cavalli, A., Fontanella, A., dkk., 2020. Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. *Journal of Cardiovascular Pharmacology*, **76**: 369–371.
- Sahebkar, A., Serban, C., Mikhailidis, D.P., Undas, A., Lip, G.Y.H., Muntner, P., dkk., 2015. Association between statin use and plasma D-dimer levels. *Thrombosis and Haemostasis*, **114**: 546–557.
- Santesmasses, D., Castro, J.P., Zenin, A.A., Shindyapina, A.V., Gerashchenko, M.V., Zhang, B., dkk., 2020. COVID-19 is an emergent disease of aging. *Aging Cell*, **19**: e13230.
- Schol-Gelok, S., van der Hulle, T., Biedermann, J.S., van Gelder, T., Klok, F.A., van der Pol, L.M., dkk., 2018. Clinical effects of antiplatelet drugs and statins on D-dimer levels. *European Journal of Clinical Investigation*, **48**: e12944.
- Schrutka, L., Seirer, B., Duca, F., Binder, C., Dalos, D., Kammerlander, A., dkk., 2019. Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding. *Journal of Clinical Medicine*, **8**: 1240.
- Schulman, S., Beyth, R.J., Kearon, C., dan Levine, M.N., 2008. Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *CHEST*, **133**: 257S–298S.
- Shi, Z. dan Puyo, C.A., 2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Therapeutics and Clinical Risk Management*, **16**: 1047–1055.
- Simmons, G., Reeves, J.D., Rennekamp, A.J., Amberg, S.M., Piefer, A.J., dan Bates, P., 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proceedings of the National Academy of Sciences of the United States of America*, **101**: 4240–4245.
- Smilowitz, N.R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J.S., dkk., 2021. C-reactive protein and clinical outcomes in patients with COVID-19. *European Heart Journal*, **42**: 2270–2279.
- Stokes, E.K., Zambrano, L., Anderson, K., Marder, E., dan Raz, K., 2020. 'Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020'. URL: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm> (diakses tanggal 29/10/2022).

- Stoneham, S.M., Milne, K.M., Nuttall, E., Frew, G.H., Sturrock, B.R., Sivaloganathan, H., dkk., 2020. Thrombotic risk in COVID-19: a case series and case-control study. *Clinical Medicine (London, England)*, **20**: e76–e81.
- Suprapti, B., Debora, L., Kusumawati, D., Ps, A.D., T, G.N., Arini, M.N., dkk., 2022. Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia. *Indonesian Journal of Pharmacy*, 381–393.
- Susilo, A., Rumende, M., Pitoyo, C., Santoso, W.J., dan Yulianti, M., 2020. 'Coronavirus Disease 2019: Tinjauan Literatur Terkini'. URL: <http://www.jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/415> (diakses tanggal 16/8/2022).
- Tang, N., Li, D., Wang, X., dan Sun, Z., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, **18**: 844–847.
- Terra, P.O.C., Donadel, C.D., Oliveira, L.C., Menegueti, M.G., Auxiliadora-Martins, M., Calado, R.T., dkk., 2022. Neutrophil-to-lymphocyte ratio and D-dimer are biomarkers of death risk in severe COVID-19: A retrospective observational study. *Health Science Reports*, **5**: e514.
- Tzotzos, S.J., Fischer, B., Fischer, H., dan Zeitlinger, M., 2020. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. *Critical Care (London, England)*, **24**: 516.
- Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., dkk., 2020. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*, **395**: 1417–1418.
- World Health Organization, 2020. 'Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020'. World Health Organization.
- World Health Organization, 2021. 'Living guidance for clinical management of COVID-19: living guidance'. URL: <https://covid19.who.int/table> (diakses tanggal 5/6/2023).
- World Health Organization, 2023. 'WHO Coronavirus (COVID-19) Dashboard'. URL: <https://covid19.who.int/table> (diakses tanggal 28/6/2023).
- Xue, Y., Sun, S., Cai, J., Zeng, L., Wang, Shihui, Wang, Suhuai, dkk., 2020. Effects of ACEI and ARB on COVID-19 patients: A meta-analysis. *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS*, **21**: 1470320320981321.

- Yang, J.-K., Lin, S.-S., Ji, X.-J., dan Guo, L.-M., 2010. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetologica*, **47**: 193–199.
- Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., dkk., 2020. Thrombocytopenia and its association with mortality in patients with COVID-19. *Journal of Thrombosis and Haemostasis*, **18**: 1469–1472.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., dkk., 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. *Journal of Intensive Care*, **8**: 49.
- Zhang, C., Wu, Z., Li, J.-W., Zhao, H., dan Wang, G.-Q., 2020. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *International Journal of Antimicrobial Agents*, **55**: 105954.
- Zhang, Z., Zhai, Z., Yang, Y., Wan, J., Xie, W., Zhu, J., dkk., 2017. Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a “real-world” study. *Journal of Thrombosis and Thrombolysis*, **43**: 540–549.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., dkk., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, **395**: 1054–1062.
- Zhu, H., Wei, L., dan Niu, P., 2020. The novel coronavirus outbreak in Wuhan, China. *Global Health Research and Policy*, **5**: 6.